Fig. 5From: Differences in anticoagulation strategy and outcome in atrial fibrillation patients with chronic kidney disease: a CODE-AF registry studyDosage of non-vitamin K oral anticoagulants (NOACs) according to eGFR in patients with chronic kidney disease. a Overall, b dabigatran, c rivaroxaban, d apixaban. In the overall NOACs, the dabigatran and rivaroxaban underdose rates were lower in patients with eGFR from 50 to 30 and < 30 mL min−1 1.73 m−2 than in those with eGFR ≥ 50 mL min−1 1.73 m−2. eGFR, estimated glomerular filtration rateBack to article page